| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Sitaglipti Phosphate is an oral medication used for the management of type 2 diabetes mellitus. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes . The drug was granted FDA approval on October 16, 2006, and is available under various brand names such as Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Zituvimet, and Zituvio .
Sitaglipti's mechanism of action involves inhibiting DPP-4, an enzyme that breaks down certain hormones in the body that help regulate blood sugar. By inhibiting DPP-4, sitagliptin leads to increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which in turn increases insulin synthesis and decreases glucagon release in a glucose-dependent manner, resulting in improved blood glucose control .
The drug is well-absorbed orally, with a bioavailability of 87%, and reaching maximum plasma concentration in about 2 hours. It has a half-life of approximately 12.4 hours and is primarily eliminated unchanged in the urine . Sitagliptin can be used in combination with other diabetes medications such as metformin or ertugliflozin to enhance glycemic control
){kind=link}